Structure Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Aleniglipron showed up to 16.3% weight loss at 44 weeks with no plateauing, and a 'start low, go slow' titration strategy improved tolerability and minimized discontinuations. No serious safety concerns were observed, and phase III will build on these findings.
Fiscal Year 2025
-
Eleniglipron demonstrated robust, dose-dependent weight loss up to 15.3% at 36 weeks, with no plateau observed and significant improvements in blood pressure and HbA1c. Tolerability improved markedly with a 2.5 mg starting dose, and no serious safety concerns were identified in over 500 patients.
-
The company is advancing oral GLP-1 and amylin programs, with key phase IIb data for Elenaprevir expected at year-end. Strategic focus includes scalability, combinability, and broad accessibility, supported by regulatory tailwinds and ongoing partnership discussions.
-
The session highlighted a transformative year for oral small molecules in obesity and diabetes, with key data readouts for lead assets expected by year-end. Strategic focus includes broadening patient access, advancing a unique portfolio, and preparing for phase three with new studies and partnerships.
-
The company is advancing a broad pipeline of oral small molecule therapies for obesity, with lead asset aaleniglipron in phase IIb trials and a strong focus on fixed dose combinations. Strategic partnerships and robust manufacturing capacity support global scalability, while a solid cash position funds operations through 2027.
-
The company is advancing oral small molecule therapies for metabolic diseases, with key phase IIb studies set to read out in Q4 2025 and a robust pipeline including GLP-1, Amylin, GIP, and Apelin programs. Strong IP position and $883.5M cash runway support ongoing development.
-
The company is advancing a broad pipeline of oral small molecules for metabolic diseases, with Aleniglipron in phase II and an amylin agonist nearing clinical entry. Differentiation centers on safety, higher dosing, and combination potential, with key data readouts expected by year-end.
Fiscal Year 2024
-
ACCT-2671, an oral small molecule amylin receptor agonist, was selected as a lead candidate for obesity, showing cagrilinotide-like efficacy and strong safety in preclinical studies. Phase I trials are planned for late 2025, with a focus on both monotherapy and combination regimens.
-
Significant progress was made in 2024 with positive phase II-A data for GSBR-1290 and the launch of phase II-B studies targeting chronic weight management. The pipeline includes innovative oral small molecules for GLP-1 and amylin, with a strong focus on combination therapies and a robust cash position supporting milestones through 2027.
-
GSBR-1290, an oral GLP-1 receptor agonist, has entered phase IIb with two studies (ACCESS and ACCESS 2) designed to optimize efficacy and tolerability, including higher dose exploration. Data are expected in late 2025, supporting rapid phase III advancement and a robust pipeline in metabolic diseases.
-
GSBR-1290, an oral GLP-1 agonist, showed 6.2-6.9% weight loss in phase IIa and is advancing to a 36-week phase IIb study, with plans for higher dosing and combination therapies. Manufacturing scale, a broad IP portfolio, and strong cash reserves support late-stage development and strategic partnerships.
-
The company is advancing a broad pipeline of oral small molecules for metabolic diseases, with GSBR-1290 showing strong efficacy and safety in phase IIa and a phase IIb trial starting in Q4. Manufacturing scalability, novel scaffolds, and parallel development of amylin and combination therapies position the pipeline competitively.
-
GSBR-1290, an oral GLP-1 receptor agonist, achieved 6.2–6.9% placebo-adjusted weight loss at 12 weeks with a favorable safety and tolerability profile. No serious liver issues were observed, and future studies will explore higher doses and slower titration to optimize efficacy and tolerability.